• Has Israel just found the cure for Covid? Experimental Covid drug cures

    From Ubiquitous@21:1/5 to All on Tue Feb 9 21:05:06 2021
    XPost: alt.tv.pol-incorrect, alt.fan.rush-limbaugh, alt.politics.usa
    XPost: sci.med.diseases

    Even with Israel’s world-leading rollout of Covid-19 vaccinations,
    drugs to treat Covid patients are in desperate need across the world.

    Two such drugs developed in Israel show great promise in clinical
    trials: EXO-CD24 and Allocetra.

    EXO-CD24, an experimental inhaled medication developed at Tel Aviv
    Sourasky Medical Center, cured all 30 moderate-to-severe cases in a
    Phase I clinical trial.

    Developed over the past six months at the hospital, EXOCD24 stops the
    “cytokine storm” – where the immune system goes out of control and
    starts attacking healthy cells – that occurs in the lungs of 5-7% of
    Covid-19 patients.

    “To date, the preparation has been tried with great success on 30
    severe patients, in 29 of whom the medical condition improved within
    two to three days and most of them were discharged home within three to
    five days. The 30th patient also recovered but after a longer time,”
    the hospital reports.

    “The drug is based on exosomes, [vesicles] that are released from the
    cell membrane and used for intercellular communication. We enrich the
    exosomes with 24CD protein. This protein is expressed on the surface of
    the cell and has a known and important role in regulating the immune
    system,” explained Dr. Shiran Shapira, director of the laboratory of
    Prof. Nadir Arber, who has been researching the CD24 protein for over
    two decades.

    “The preparation is given by inhalation, once a day, for only a few
    minutes, for five days,” Shapira said.

    She said the experimental treatment has two unique characteristics. The
    first is that it inhibits the over-secretion of cytokines. The second
    is that it is delivered directly to the lungs and therefore has no
    systemic side effects that injected or oral drugs can cause.

    “Even if the vaccines perform their function, and even if no new
    mutations are produced then still in one way or another the corona will
    remain with us,” said Arber, director of the medical center’s
    Integrated Cancer Prevention Center. “To this end, we have developed a
    unique drug, EXO-CD24.”

    Arber added that this advanced preparation “can be produced quickly and efficiently and at a very low cost in every pharmaceutical facility in
    the country, and in a short time globally.”

    Prof. Ronni Gamzu, CEO of the medical center, said, “Prof. Arber’s
    results for first-phase research were excellent and gave us all
    confidence in the method he has been researching [here] for many years.
    I personally assisted him in further obtaining the approvals from the
    Ministry of Health for further research.”


    Meanwhile, Enlivex Therapeutics last week reported positive results
    from a multi-center Phase II clinical trial of its experimental Covid-
    19 immunotherapy drug Allocetra in severe and critical Covid-19

    We reported in October that five Covid-19 intensive care patients were discharged from Hadassah University Medical Center in Jerusalem after
    treatment withAllocetra.

    Nine severe and seven critical Covid-19 patients were treated with
    Allocetra in the Phase II clinical trial. Fourteen of them recovered
    and were discharged from the hospital after an average of 5.3 days.

    The Phase II trial originally was expected to enroll 24 patients but
    was “completed early in support of anticipated accelerated regulatory
    filings of the trial’s positive safety and efficacy data,” Enlivex

    Altogether, 19 out of 21 Phase II and Phase Ib Allocetra trial patients recovered and were discharged from the hospital after an average of 5.6
    days. Most of the patients in both studies had pre-existing risk
    factors such as male gender, obesity and hypertension.

    “The results we have seen from the 12 Covid-19 patients treated to date
    with Allocetra are exciting,” said Prof. Vernon van Heerden, head of
    the General Intensive Care Unit at Hadassah and the lead investigator
    of both clinical trials.

    “The Phase II patients who have been discharged from the hospital are
    currently healthy. We believe that these compelling results have
    demonstrated the safety and efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex’s product candidate to
    benefit severe and critical Covid-19 patients as well as others
    suffering from cytokine storms and organ dysfunctions across various
    clinical indications.”

    Allocetra is based on the research of Enlivex chief scientific and
    medical officer Dr. Dror Mevorach, head of internal medicine and of one
    of Hadassah’s coronavirus wards. It works by restoring balance to the
    immune system.

    Mevorach said Allocetra “may have utility as a safe and efficacious
    treatment … regardless of the specific coronavirus mutation that
    afflicted the patients, and across different life-threatening, high
    mortality clinical indications with high unmet medical needs.”

    For over 16 years, ISRAEL21c has brought you the faces and places of
    Israel every day, spreading the word about Israel to millions of people
    in virtually every country around the globe. First of its kind, our
    content is originally researched, written and produced by seasoned
    experts directly from Israel.

    We cannot do this without financial support from people like you.
    Become a GEM member and enjoy exclusive briefings from our staff and
    more - for $18 a month.

    Trump won.

    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)